| abstract |
The present invention relates to the use of an endothelin receptor antagonist, an endothelin receptor antagonist, or an endothelin receptor antagonist, any of pirfenidone and interferon-γ for the manufacture of a medicament for the treatment of early idiopathic pulmonary fibrosis It relates to the use of a pharmaceutical composition containing either of these. A further embodiment of the present invention, the endothelin receptor antagonist is an endothelin receptor dual antagonist or endothelin receptor mixed antagonists, used above, and endothelin receptor antagonists, to the ET A receptor The use as described above, which is a selective endothelin receptor antagonist that selectively binds to. |